Overview

Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis

Status:
Recruiting

Trial end date:
2023-11-01

Target enrollment:
0

Participant gender:
All

Summary

Endophthalmitis is a severe inflammatory eye condition with profound impairment of vision, which can lead to irreversible visual loss and requires immediate treatment. There is no way to completely prevent endophthalmitis, however, through prophylactic methods, it is possible to reduce its incidence. Currently, the only technique that has reached category II of evidence in reducing the risks of endophthalmitis is the use of 5% povidone-iodine eye drops, moments before surgery. In 2007, the European Society of Cataract and Refractive Surgery (ESCRS) released a large multicenter randomized clinical trial, with data on the reduction in the rates of endophthalmitis, using the intracameral antibiotic therapy technique of perioperative cefuroxime. However, much is discussed about the risks related to the technique, such as dilutional errors, contamination, anaphylaxis and cost-effectiveness, which still makes the conduct debatable. The study evaluates the use of intracameral Moxifloxacin 0.5% (Vigamox®) as prophylaxis in cases of endophthalmitis after open ocular trauma;

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Federal University of São Paulo

Collaborators:

Luis Filipe Nakayama
Somaia Mitne Teixeira
Vinicius Campos Bergamo

Treatments:

Moxifloxacin

Criteria

Inclusion Criteria:

- open globe trauma

Exclusion Criteria:

- endophthalmitis at the beginning